HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Permissions Request Permissions Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (22) Citing Articles via Google Scholar Google Scholar Articles by Stock, S. Articles by Lauterbach, K. W. Search for Related Content PubMed PubMed Citation Articles by Stock, S. Articles by Lauterbach, K. W.

Asthma: prevalence and cost of illness

Institute of Health Economics and Clinical Epidemiology of the University of Cologne,

CORRESPONDENCE: S. Stock, Institute of Health Economics and Clinical Epidemiology of the University of Cologne, Gleueler Str. 176–178, 50935 Cologne, Germany. Fax: 49 2214786675. E-mail: Stephanie.Stock@medizin.uni-koeln.de

Keywords: Asthma, cost, Germany, health insurance, prevalence

Received: October 17, 2003
Accepted August 20, 2004

The purpose of this study was to estimate the prevalence and cost of illness of asthma in Germany by retrospectively analysing routine health insurance data.

This analysis investigated claims data from all insured persons of six large sickness funds. Insurants with asthma were identified via the International Classification of Diseases (ninth revision) diagnosis and the Anatomical Therapeutic Chemical Classification System Code for regular medication prescriptions. Costs for hospital care, medication and sick benefit were taken from claims data. Costs for rehabilitation, premature death and early retirement were estimated using the human capital approach and data from national statistics.

Prevalence of asthma in the German statutory health insurance was 6.34%. Total costs for asthma, including direct and indirect costs, were calculated at \#8364;2.74 billion during 1999.

The prevalence of asthma in the German statutory health insurance has previously been estimated to be 4–6%. The results of this large study show the prevalence of asthma in the German social insurance system to be 6%. The study also indicates that there is room for substantial savings in the German social insurance system, with indirect costs amounting to 74.8% of total costs and payment of sick benefits through the sickness funds amounting to 58.3% of indirect costs. These costs may be reduced with better asthma control in patients.

This article has been cited by other articles:

				P. Bradding Mast cell regulation of airway smooth muscle function in asthma Eur. Respir. J., May 1, 2007; 29(5): 827 - 830. [Full Text] [PDF]

				C. K. W. Lai, Y-Y. Kim, S-H. Kuo, M. Spencer, A. E. Williams, and on behalf of the Asthma Insights and Reality in As Cost of asthma in the Asia-Pacific region Eur. Respir. Rev., June 1, 2006; 15(98): 10 - 16. [Abstract] [Full Text] [PDF]

				D. Vervloet, A. E. Williams, A. Lloyd, and T. J. H. Clark Costs of managing asthma as defined by a derived Asthma Control TestTM score in seven European countries Eur. Respir. Rev., June 1, 2006; 15(98): 17 - 23. [Abstract] [Full Text] [PDF]

				S. Mangiapane, M. Schulz, S. Muhlig, P. Ihle, I. Schubert, and H.-C. Waldmann Community Pharmacy-Based Pharmaceutical Care for Asthma Patients Ann. Pharmacother., November 1, 2005; 39(11): 1817 - 1822. [Abstract] [Full Text] [PDF]